Drug Trial Radar · NCT05896293
Kisspeptin Administration Subcutaneously to Patients With IHH
Last checked: Nov 20, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Feb 3, 2023
Primary completion
May 2028
Study completion May 2028
Sponsor
- Lead sponsor
- Stephanie B. Seminara, MDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 9, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in men and women with idiopathic hypogonadotropic hypogonadism (IHH). The investigators are also examining whether kisspeptin can help women release eggs from their ovaries. Kisspeptin will be administered SC for two weeks in a pulsatile fashion. Ultrasound monitoring of ovarian follicular growth (for women) and frequent blood sampling (every 10 minutes for up to 70 minutes) will be performed to assess the physiologic response to kisspeptin over time. Funding Source: FDA OOPD
Conditions
- Hypogonadotropic Hypogonadism
Interventions
kisspeptin 112-121Drug
SC administration of kisspeptin for two weeks (pulsatile, every 60-240 minutes)
leuprolide acetateDrug
Single SC bolus
Primary outcomes
What the sponsor says the trial is designed to measure.
- Average change in luteinizing hormone (LH) pulse amplitudeTime frame: 2 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.